CCTG

LY.18 (ML40080, A17-190)

NCT04161248

LY18

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Status:

Opening Soon

26459-200.png

I

Phase

Line of Therapy.png

2nd

Line of Therapy

Disease Stage.png

Relapsed / Recurrent / Refractory

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Venetoclax

Treatment Arms

o Experimental: Venetoclax + R-GDP